

Index

- 4-OH- tamoxifen 38, 140, 147
 – breast cancer patients 140
 – estrogen-like actions 147
 – second binding site 38
 5-butyloxazole unit 351
 5-ring heterocycles 213
 6-phenyl-naphthalene series 85
 7-desmethyl derivative (DMC) 102
 7,12-dimethylbenzanthracene (DMBA) 159
- a**
- acrylic acid-based side-chain 105
 acrylic acid variants 91
 acute phase protein 423
 Addison disease 2, 305
 adipose tissue 373, 432
 adrenal glands 432
 agonist-bound steroid hormone receptor 249
 aldosterone antagonism 411
 aldosterone-producing adrenal tumor 410
 aldosterone synthase 434
 aldosteronism 410
 allogeneic transplantation 339
 all *trans*-retinoic acid (ATRA) 422
 Alzheimers disease 136
 American Cancer Society 127
 amino acid sequence 250
 – DBD 250
 – homology 250
 aminoalkoxy chain 102
 anabolic androgenic steroids (AAS) 253
 androgen-insensitivity syndrome (AIS) 251
 androgen receptor (AR) 28, 87, 205, 225, 249,
 251, 410
 – binding requirements 34
 – function 249
 – pathogenic mutations 251
 – polymorphisms 251
 – previous studies 34
 – structure 249
 androgen-responsive elements (ARE) 251
 androgen target tissues 249
 – central nervous system 249
 – liver 249
 – prostate 249
 – skeletal muscle 249
 androgenic agonist activity 267
 angiotensin-converting enzyme (ACE)
 inhibitor 411
 antiandrogen withdrawal syndrome 252
 antibody-dependent cellular cytotoxicity 331
 antigen-presenting cells (APCs) 331
 antigen-specific reactions 337
 antigen-specific T cell activation 330, 332
 antigluocorticoid 237, 238
 – applications 237
 – effects 238
 antihormonal-resistant breast cancer 167
 antiinflammatory actions 345, 419
 antiinflammatory cytokines 333, 345
 antiinflammatory drugs 319
 antiminerlocorticoid activity 410
 antipsychotic drugs 437
 – chlorpromazine 437
 – clozapine 437
 – fluphenazine 437
 – haloperidol 437
 – olanzapine 437
 – raclopride 437
 antiuterotrophic effects 12
 AR antagonists 252
 – bicalutamide 252
 – hydroxyflutamide 252
 – nilutamide 252

- AR binding affinity 253
 - AR-coactivator interactions 28, 31, 39
 - evaluation 31
 - AR-dependent anabolic activities 284
 - AR-dependent transcriptional activation 257
 - AR-interacting peptides 31
 - AR-interacting proteins 281
 - AR-ligand interactions 276
 - AR gene targets 251
 - enhancer region 251
 - promoter 251
 - AR ligands 252, 255, 263, 276
 - nonsteroidal 255, 276
 - steroidal 276
 - AR mutations 252
 - AR phosphorylation 283
 - arachinoic acids 419
 - aromatase inhibitor (AI) 135
 - Arzoxifene 93, 94, 161
 - atherosclerosis 370
 - athymic mice 155
 - E2-dependent MCF-7 breast tumors 155
 - atrial natriuretic peptide (ANP) gene 419, 421
 - autoimmune diseases 354
 - MS 354
 - RA 354
 - autoimmune prostatitis 339
 - autoimmune thyroiditis 339
 - azaindole trifluoropentanol 315
 - synthesis of 315
 - azasteroidal template 265
- b**
- basal transcription initiation complex 309
 - binding site 309
 - basic side-chain (BSC) 66
 - bazedoxifene 94, 162
 - benzopyranone derivatives 102
 - benzothiophene analogs 100
 - benzothiophene arzoxifene 161
 - benzothiophenes 77, 91
 - benzoxazine system 213
 - benzoylaminobenzoic acids 376
 - bicyclic ring structure 213
 - bicyclononene ring systems 70, 87
 - binding assays 204
 - bioactive lipid-soluble mediator pathway metabolites 442
 - blocking estrogen synthesis 135
 - bone metabolism 325
 - bone mineral density (BMD) 254, 287
 - bone recruit coactivator complexes 282
 - bone-specific agent 154
 - breast cancer 142, 169
 - pure antiestrogen therapy 169
 - treatment 142
 - breast cancer cell lines 51
 - breast cancer mortality 127
 - breast cancer therapies 47
 - breast cell-based assays 10
- c**
- calcitriol derivatives 347, 351
 - calcium homeostasis 325, 421
 - carbonyl ene reaction 317
 - carcinogen-induced rat mammary cancer 151
 - carcinogen-induced rat mammary tumors 153
 - cardiovascular diseases 421, 422
 - cardiovascular system 10, 409, 415
 - cell-based assays 11, 412, 413
 - transactivation 71, 77, 110
 - cell-impermeable ligands 56
 - cell-permeable ligands 56
 - cell culture experiments 337
 - cell proliferation 325, 433
 - cell type-specific coregulators 133
 - Central Drug Research Institute 101
 - central nervous system (CNS) 88, 249, 334, 415, 432
 - chloramphenicol acetyltransferase (CAT) 204
 - CHO cell-based transactivation assay 110
 - cholesterol lowering activity 418
 - chromenoquinoline system 216
 - chronic heart failure (CHF) 411
 - chronic kidney disease (CKD) 287
 - chronic obstructive pulmonary disease (COPD) 287
 - classic pathway mediates estrogen response 58
 - reproductive tissues 58
 - classic synthetic glucocorticoids dexamethasone 11
 - beneficial effects 11
 - long-term treatment 11
 - side-effects 11
 - Clostridium sordellii* 232
 - coactivator-binding groove 34, 35, 38
 - coactivator binding inhibitor (CBI) 26
 - coactivator-complex proteins 132
 - coactivator-receptor-DNA interactions 132
 - coactivator proteins 371
 - cofactor interaction screening 14
 - competition factor (KF) 204
 - computational based approach 37
 - confidence interval (CI) 143

Conn's syndrome 410
 Continuing Outcomes Relevant to Evista (CORE) 92, 143
 contraceptive potential 234
 coregulator proteins 250
 C-reactive protein 163
 – dose-dependent reduction 163
 Cushing's syndrome 238, 305
 CV1 cells 211, 214
 – aryl groups 216
 – PRE-Luc transactivation assay 214
 cyclin-dependent kinase inhibitor 434
 cyproterone acetate 6, 207, 252, 255
 cysteine-rich zinc finger motifs 203

d

D₁L dicysteine motif 35
 dependent allergic asthma model 338
 depot medroxy progesterone (DMPA) 235
 desoxycorticosterone acetate (DOCA) 419
 dexamethasone 333, 337
 DHT-dependent tissues 281
 diaryl AR ligands 259
 diaryl AR templates 259
 diarylsalicylaldehyde core 101
 – estrogenic activity 101
 diaryltetrahydronaphthalene derivative 156
 diethylstilbestrol (DES) 49, 76
 dihydrophenanthrene ring system 82
 dihydrophenanthrenes 81
 dihydroquinoline system 213
 dimethyl cyclopropylmalonate 351
 diphenylmethyl alkene derivatives 91
 diverse peptide libraries 33
 DNA-binding domain (DBD) 48, 130, 203, 225, 249, 369, 435
 – zinc finger motifs 369
 DNA-bound transcription factors 308
 – STAT5 308
 DNA chromatin 371
 DNA-ER-coactivator complex 132
 DNA-regulatory elements 1
 dopamine (DA) neurons 432
 dopaminergic cell line 434
 dopaminergic neurons 444
 drospirenone 6, 208, 411
 drug discovery 47
 – challenges 47
 dual-profile estrogens 113
 dual-profile ligands 68
 dual agonists 379
 dysfunctional uterine bleeding 236
 dyslipidemia 370
 – treatment of 370

e

electron-withdrawing group (EWG) 278
 electrostatic interactions 278
 enclomiphene citrate 89
 endocrine abnormalities 288
 – hypogonadism 288
 – hyposomato tropinism 288
 endocrine regulatory systems 1
 – discovery 1
 endogenous ligands 367
 endogenous target genes 15
 endogenous vitamin D levels 421
 endometrial hyperplasia 238
 endometrial thickening 238
 endometriosis 234
 – treatment 234
 endoxifen 140
 – plasma concentrations 140
 – plasma levels 140
 epidermal growth factor (EGF) 132
 ER agonist-directed therapy 47
 ER-coactivator interaction 29, 30, 39
 – evaluation 29
 ER α -containing cells 15
 ER-directed drug discovery 10
 ER α gene 130
 – transcriptional activation 130
 ER-mediated gene transcription 29
 ER-mediated transcriptional activity 65
 ER-modulating properties 9
 ER-negative invasive breast cancer 143
 ER-positive breast cancer cells 55, 145
 – growth regulation 145
 ER-positive invasive breast cancer 143
 ER-related receptor (ERR) 48
 ERR family members 54
 – possible roles 54
 ERR ligand-binding preferences 54
 ER α -selective ligands 53
 ER α -selective agonists 51, 69, 88, 110, 115
 ER subtype-selective ligands 66
 ER subtype-selective modulators 10
 estradiol-dendrimer conjugates 58
 estradiol-induced gene transactivation 110
 – high inhibitory activity 110
 estradiol-like activity 9
 estradiol-mediated protection 50
 estradiol-mediated transcriptional activity 30
 estradiol-regulated genes 15
 estrogen-binding receptor 47, 57
 estrogen-dependent endometrial proliferation 229
 estrogen-induced proliferation 204
 estrogen-like actions 136

- estrogen-producing gland 267
 - estrogen-receptor complexes 150
 - estrogen-responsive breast cancers 3
 - estrogen-responsive target genes 132
 - estrogen receptor (ER) 6, 65, 225, 367
 - ligands 280, 409
 - biology 65
 - research 3
 - estrogen response element (ERE) 30, 130
 - estrogen-targeted drugs 47
 - ether-linked phenyl ring 276
 - ether-linked propionanilides 257
 - ethinyl estradiol analogs 58
 - experimental autoimmune encephalomyelitis (EAE) 334
 - expressed sequence tag (EST) 6
 - extensive clinical trials 155
 - extracellular signal-regulated kinase (ERK) 55, 437
- f**
- farnesoid X receptor (FXR) 8
 - fatty acids 419
 - five-membered heterocycles 69, 105
 - flutamide analogs 209
 - follicle-stimulating hormone (FSH) 71, 140, 201
 - Food and Drug Administration (FDA) 95, 137, 232, 373
 - full antagonists 111
 - full-length coactivators 29
 - Fulvestrant 111, 165, 167, 168
- g**
- GC-induced leucine zipper (GILZ) 310
 - GC-like compounds 306
 - antiinflammatory activity 306
 - immunomodulatory activity 306
 - GC-responsive elements (GREs) 308
 - gene expression 409
 - profiling 14, 15
 - regulators of 409
 - gene transcription 309
 - genome-wide scale 14
 - genome-wide screens 14
 - glucocorticoid receptor (GR) 2, 205, 225, 410
 - drug discovery 2
 - glucocorticoid receptor ligands 305
 - glucose metabolism 308, 418
 - gonadotropin-releasing hormone (GnRH) superagonist 234
 - G-protein binding 56
 - G-protein-coupled receptor (GPCR) 48, 437
 - GPR30 55, 56
 - estrogen signaling 56
 - functions 55
 - knockout mice 55
 - localization 56
 - physiological roles 55
 - GR 307, 308, 309
 - action 307
 - AF domains 309
 - molecular mechanisms 308
 - X-ray structures 308
 - GR activities 310
 - GR ligands 306, 310, 311, 320
 - dissociated 311
 - GR-mediated gene regulation 318
 - GR monomers 309
 - GR pathways 320
 - gram-positive bacillus 232
 - Grignard reaction 313
 - growth-inhibitory genes 134
 - growth hormone 284
 - growth-promoting genes 134
- h**
- halofenic acid 380
 - HDL cholesterol 423
 - levels 423
 - heat shock protein (HSP) 130, 250
 - HeLa cell-based transactivation assay 76
 - helix-groove interaction 26
 - helix-stabilized cyclic peptides 35
 - helix mimetic biaryl scaffolds 38
 - hepatic lipid metabolism 370
 - heterodimer activators 442
 - heterodimer-selective RXR modulator 381
 - high-affinity ER ligands 55
 - high-affinity radiolabeled ligand 374
 - high-density lipoprotein (HDL) 254
 - cholesterol 140
 - high-intensity electric field 237
 - high-risk women 141
 - coronary heart disease 141
 - high-throughput analysis 15
 - methods 15
 - high-throughput genome-wide chromatin immunoprecipitation methods 15
 - high-throughput library screen 38
 - high-throughput methods 16
 - high-throughput screening (HTS) 9
 - activities 78
 - high-throughput screening formats 204
 - high blood pressure 373
 - high density lipoprotein (HDL) 419
 - hinge variations 92
 - hippocampal pyramidal neurons 433

- histone acetyl transferase (HAT) 27
 – activity 281
 histone deacetylase (HDAC) functionalities 27
 – activity 281
 hormone-binding domain 226
 – N-terminal region 226
 hormone progesterone 223
 hormone-response elements 435
 hormone receptors 367
 hormone replacement therapy (HRT) 127, 236
 – postmenopausal women 236
 hormone-sensitive promoter 204
 human chorionic gonadotropin (hCG) 201
 human endometrial carcinoma 143
 human hypertension 411
 human inflammatory diseases 354
 human leukocyte antigen (HLA-DR) 332
 human nuclear receptors 16
 – functions 16
 – future developments 16
 hydrogen-bond acceptor 278, 279
 hydrogen-bond donation 278
 hydrogen-bond donor 278, 279
 hydrogen-bond interactions 205
 hydrogen-bond network 131, 145
 hydrogen-bonding contacts 34
 hydrogen-bridge network 66
 hydrophilic interaction 276
 hydrophobic amino acid 33
 hydrophobic groove 37
 hydrophobic interactions 278
 hydrophobic van der Waals contacts 132
 hydroxyflutamide-like archetype 270
 hydroxyflutamide (OHF) 32
 hyperaldosteronism 410
 hypercalcemia 348
 hypercalciuria 348
 hypothalamic-pituitary-gonadal axis 287
 hypothalamic-pituitary-ovarian (HPO) axis 50, 100, 158
 hypothalamic neurons 56
 – calcium mobilization 56
- i**
 idoxifene 152
 imide bond 256
 – hydrolysis of 256
 iminothiazolidines 216
 immature rat pituitary gland cells 145
 – primary cultures 145
 immune cells 329
 immune diseases 325
 immune system 326, 421
 – activated macrophages
 immunocompetent cells 325
 immunomodulatory drugs 354
 immunomodulatory therapy 345
 immunosuppressive drugs 319, 329
 – dexamethasone 329
 indole 315
 – AR ligands 275
 – synthesis of 315
 inflammatory bowel disease (IBD) 337
 inflammatory cytokines 431
 inflammatory response markers 419
 – endothelin-1 419
 – interleukins 419
 – tumor necrosis factor- α 419
 inflammatory signals 432
 insulin-like growth factor 1 (IGF-1) 71, 132
 – expression 71
 insulin signaling pathway 380
 integrated estrogen signaling 58
 interferon (IFN)- γ secretion 328
 – inhibition of 328
 interleukin (IL)-2 328
 – inhibition of 328
 interleukin (IL)-8 pathway 281
 intracellular signaling cascades 280
in vitro AR agonists 263
in vitro assays 345
in vitro fertilization programs 235
 – potential use 235
in vivo assays 345
 iodine containing molecules 414
 isolated nuclear receptor genes 8
- k**
 Kennedy's disease 252
 keoxifene 136
 Kinase signaling cascades 134
- l**
 L-enantiomer 101
 lasofoxifene 100, 103, 156, 157
 – isochromanes 103
 – isothiochromane analogs 103
 LDL cholesterol 418, 423
 lean body mass (LBM) 257
 levormeloxifene 102, 157, 158
 – estrogen-like effect 158
 LH-releasing hormone superagonists 164
 life-threatening side effect 232
 ligand-activated nuclear receptor 436
 ligand-activated transcription factor 309
 ligand aldosterone 410

- ligand-binding domain (LBD) 12, 25, 203, 226, 367, 369, 435
 - binding pocket 25
 - ligand-binding pocket (LBP) 130
 - ligand-binding site 66, 68, 376
 - ligand-bound nuclear hormone receptor 423
 - ligand-dependent transactivation 439
 - ligand-dependent transgene expression 237
 - ligand-independent activity 147
 - ligand-ligand-binding domain (LBD) complex 66
 - ligand-screening assays 15
 - linoleic acids 419
 - lipid abnormalities 379
 - lipid homeostasis 367
 - lipid-lowering agents 419
 - lipid metabolism 414, 420
 - lipid transporters 423
 - lipophilic ligands 431
 - lipoprotein 370
 - liposomes encapsulating steroids 306
 - liver receptor homolog-1 367
 - liver X receptors (LXRs) 367, 422
 - LMW modulators 438
 - long-acting agents 142
 - long-term breast cancer therapy 136
 - low-affinity molecules 259
 - low-density lipoprotein (LDL) 254
 - cholesterol 140
 - receptor 415
 - low-molecular-weight (LMW) 437
 - low nanomolar AR binding 273
 - lower triglyceride (TG) 370
 - Luc reporter gene 213
 - luciferase reporter gene 439
 - assay 439
 - luteinizing hormone (LH) 140, 201, 250
 - surge 235
- m**
- MBO amino pyruvate carbonyl 317
 - McPhail assay 226
 - McPhail index 204
 - medroxyprogesterone acetate (MPA) 207
 - metabolic disorders 421
 - metabolic syndrome 423
 - methotrexate (MTX) 438
 - methyl benzoxazinoneamides 313, 315
 - microarray technology 14
 - microsphere-based *in vitro* binding assay 91
 - phage display-derived peptides 91
 - mifepristone 223, 229, 232, 233, 234, 235, 236, 237
 - mineralocorticoid receptor (MR) 205, 225, 312
 - mitochondrial oxidative phosphorylation 418
 - mitogen-activated protein kinase (MAPK) 283
 - mixed lymphocyte reactions (MLRs) 332
 - modern chromatographic methods 2
 - molecular modeling 156
 - monocytic cell line 331
 - morphine-addicted rat model bazedoxifene 94
 - mouse mamma tumor virus (MMTV) promoter 204
 - MR antagonists 410, 413
 - activity 411
 - progesterone 413
 - multichannel blocker 416
 - multiple outcomes of raloxifene evaluation (MORE) 143
 - multipotent secosteroid hormone 325
 - murine cells 337
 - myocardial fibrosis 410, 419
 - myostatin inhibitors 284
- n**
- N-Acylthiadiazolines 13
 - N-desmethyltamoxifen ratios 140
 - N-terminal domain (NTD) 249, 252
 - National Institute of Child Health and Human Development 224
 - National Surgical Adjuvant Breast and Bowel Project 141
 - natural killer (NK) cells 335
 - natural progesterone 4
 - effect 4
 - nerve growth factor 367, 432
 - new computer algorithm (NUBIsScan) 15
 - nitrogen-linked aryl groups 265
 - nitrogen variants 103
 - node-negative breast cancer 141
 - long-term adjuvant therapy 141
 - node-positive breast cancer 137
 - postmenopausal women 137
 - node-positive disease 135
 - nongenomic pathways mediate estrogen responses 58
 - nonreproductive tissues 58
 - nongenomic signaling pathways 283
 - nongynecological applications 236
 - nonnatural cyclic peptides 34
 - nonobese diabetic (NOD) 336
 - nonphysiologic secretory effect 239
 - nonsteroid receptor modulators 13

- nonsteroidal aldosterone antagonists 412
 nonsteroidal androgen antagonist 255
 – flutamide 255
 nonsteroidal antiandrogen 255, 256
 nonsteroidal AR ligands 257, 261
 nonsteroidal progestins 209
 nonsteroidal SARMs 257
 – discovery 257
 norethindrone 5
 – double-bond isomer 5
 novel nuclear receptor-interacting
 cofactors 14
 novel signalling pathways 15
 nuclear hormone receptors 249, 283, 409,
 423
 – characteristic 409
 nuclear magnetic resonance 2, 436
 nuclear receptor-coactivator interaction 27,
 34
 nuclear receptor-cofactor complexes 26
 nuclear receptor-cofactor inhibitors 35
 nuclear receptor-cofactor interaction 25, 28,
 33
 – drug Target 28
 – evaluation 28
 – inhibitors 33
 nuclear receptor-cofactor interaction 26, 39
 – biological validity 39
 – pharmacological effects 39
 nuclear receptor-regulated gene
 transcription 37, 435
 nuclear receptor corepressor (NCoR) 226,
 310
 nuclear receptor drug discovery 9, 13
 – modern methods 13
 – recent progress 9
 – technologies 13
 nuclear receptors 1, 28, 369, 409, 412, 418,
 431, 432, 436
 – characteristic of 369
 – expression of 444
 – first drugs 1
 – NR4A homodimers 432
 – steroid hormone receptors 431
 – structure 369
 Nur-responsive element (NurRE) 432
- o**
- oral contraceptives 3
 orally active pure antiestrogen 160
 – EM-652 159
 orphan receptors 1, 16, 25, 367
 – Nurr1 16
 osteoporosis 305
- ovarian granulosa cells 134, 434
 OVX-rat model 96, 102, 107
 oxazole calcitriols 348
 oxygen variants 101
- p**
- PA mifepristone 229, 230
 – single-dose administration 229
 palmitic acids 419
 parathyroid hormone (PTH) 284, 326
 Parkinson's disease 437
 partial agonists 379
 P-dependent growth factors 230
 pegylated (PEG) liposomes 306
 peptide hormones 431
 peptide interaction profiling 105
 peroxisomes 370
 – proliferation of 370
 peroxisome-proliferator-activated receptor
 (PPAR) 8, 382, 409
 phage display-derived peptides 33
 phage display peptides 33
 pharmacokinetic (PK) properties 83
 phorbol myristate acetate (PMA) 338
 photoreceptor cell-specific receptor (PNR) 6
 photosensitized isomerization 351
 piperazine analogs 92
 piperidine-substituted analog 108
 pituitary gonadotropins 254
 placebo-controlled trials 235
 plasma membrane-associated signaling
 pathways 251
 polar surface area (PSA) 100
 polyunsaturated fatty acids 370
 post-myocardial infarction (MI) 411
 postmenopausal osteoporosis 94
 – treatment 94
 postmenopausal patients 153
 – breast cancer treatment 153
 postmenopausal vaginal syndrome 90
 posttranslational modification 65, 282, 369
 – phosphorylation 282
 – sumoylation 282
 potent insulin sensitizer 381
 PPAR activation 370
 PPAR cofactors 371
 PPAR isotypes 369
 – selectivity 377
 PPAR ligands 380, 381
 PPAR response elements (PPREs) 371
 PPAR-RXR heterodimer 371, 378
 PR antagonist (PA) 223
 PR-mediated transcriptional activities 203
 PR-positive advanced breast cancer 154

- pregnancy termination 232
 pregnane X receptor (PXR) 6
 progestational symptoms 410
 – gynecmastia 410
 progesterone-dependent enzyme 229
 progesterone-dependent genes 236
 progesterone receptor (PR) 4, 135, 201, 410
 – antagonist 223
 – development 4
 – functional aspects 202
 progesterone response element (PRE) 226
 proinflammatory cytokines 305
 proinflammatory proteins 320
 proinflammatory stimuli 343
 proinflammatory transcription factors 320
 propionanilide linker segment 259
 propylpyrazole triol (PPT) 50, 66
 prostate cancers 251, 252
 prostate hypertrophy 284
 prostate-specific antigen (PSA) 259
 prostate tumors 252
 prostatic hyperplasia 254
 prostatic intraepithelial neoplasia 267
 protein catabolism 288, 320
 protein–protein interactions 25, 29, 38, 132, 309
 pulmonary eosinophilic inflammation 337
 pure antiestrogens 89, 164
 pyrazole corticoids 318
 pyrazoline scaffold 210
- q**
- quinolines 75
 – based series 11
 – ligands 105
- r**
- raloxifene 136, 137, 142
 raloxifene-induced cellular hypertrophy 162
 raloxifenes benzothiophene moiety 145
 – hydroxyl group 145
 randomized aldactone evaluation study (RALES) 411
 receptor-associated protein 438
 receptor-binding assay 71, 72
 receptor-peptide interactions 14
 relative binding affinity (RBA) 204
 relative risk (RR) 143
 renal disease 422
 renin-angiotensin-aldosterone system 422
 reporter gene assay 438
 retinoic acid receptors (RARs) 422
 retinoic acid treatment 433
 retinoid X receptor (RXR) 328, 367, 415, 422, 432
 rheumatoid arthritis (RA) 306, 339
 – models of 339
 Rupperts reagent 314
- s**
- Salsola tuberculatifformis* 319
 salt-sensitive hypertension 413
 sarcopenic disorders 288
 sarcoplasmic reticulum 418
 second-line agent 156
 second-line therapy 156, 167
 selective AR modulators (SARMs) 256, 259, 279, 281, 283, 286, 287, 290
 – activities 276
 – cancer cachexia 286
 – chemotypes 259
 – design 259
 – development 259
 – genomic effects 283
 – molecular Basis 276
 – non-genomic 283
 – role 286
 – templates 261, 263, 272, 273, 275
 – therapeutic applications 290
 – tissue selectivity 280
 selective ER modulators (SERMs) 9, 127, 257, 283
 – genomic effects 283
 – non-genomic 283
 selective nuclear receptor modulation 12
 – theory 12
 selective PR modulator (SPRM) 223
 SERM antiestrogenic action 144
 – mechanism 144
 SERM-mediated estrogenic activity 148
 SERM 4-OH-tamoxifen 54
 SERM-receptor complexes 150
 SERM-type antagonists 66, 88
 SERM-type estrogens 82, 111
 SERM-type ligands 66
 SERM-type scaffolds 95
 serotonin reuptake inhibitor 140
 sex hormone-binding globulin (SHBG) 140, 250
 sex steroids 254
 – biosynthesis of 254
 Shanghai Institute for Biological Sciences 76, 108
 side-chain-side-chain disulfide bridges 35
 side-chains mimicking Leu 37
 silencing mediator for retinoid and thyroid receptors (SMRT) 310

- silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) 226
- six-membered heterocycles 69, 105
- six-membered pseudocycle 101
- skeletal muscle 370, 373
- small-molecule ligands 9, 25, 27
- small-molecule regulators 438
- small interfering RNA (siRNA) 433
- spiro-ether group 224
- steroid hormone receptors 250, 412
- steroid receptor coactivator (SRC) 30, 149
- steroid receptor family 409
- steroid receptor modulators 13
- steroidal androgens 284
- therapy 253
- steroidal ER α agonists 70
- steroidal ER β -selective estrogens 86
- steroidal progestins 206
- development 206
- properties 206
- steroidal SERM-type antagonists 108
- steroidogenic factor 367
- stilbene derivative tamoxifen 9
- stress-related diseases 2
- structure-activity relationship (SAR) 81, 257, 377
- structure-based drug design approaches 9
- structure-function relationships 146
- study of tamoxifen and raloxifene (STAR) 92, 130
- subtype-selective estrogens 65, 68
- t**
- T cell-inhibitory effect 332
- T cell inhibitory Ig-like receptor 329
- T regulatory cells 331
- tamoxifen 3, 88, 89, 111, 132, 136, 137, 138, 140, 141, 170
- tamoxifen-ER complex 148, 150
- conversion 150
- estrogen-like effects 148
- tamoxifen-induced drug resistance 147
- tamoxifen-stimulated breast 167
- laboratory models 167
- tamoxifen-stimulated tumor growth 137, 153
- long-term toxicology 141
- tamoxifen treatment 137
- target-tissue-specific modulator 136
- TATA box element 237
- Tebbe reaction 317
- terminal uridine deoxynucleotidyl transferase 439
- testosterone-induced prostate cancer 271
- testosterone replacement therapies (TRT) 284
- tetracyclic benzothiophenes 107
- tetracyclic chromene derivatives 107
- tetrahydrochrysenes (THC) 113
- tetrahydrofluorenones 82
- tetrahydroisoquinolines 75, 103, 104
- tetrahydronaphthalene benzoxazinoneamide 317
- synthesis of 317
- tetrahydroquinoline scaffold 104
- tetralin analogs 100
- therapeutic protein 237
- expression 237
- thiadiazoleacrylamide 54
- thiazole calcitriols 349
- thiazolidinedione (TZD) 8, 373
- thiazolidinone ring structure 217
- thick-walled muscular arterioles 239
- thin-walled vessels 239
- prominent aggregation 239
- thiol-containing amino acids 35
- third-generation drug discovery effort 8
- three-dimensional nuclear magnetic resonance 212
- thyroid hormone receptor 328, 367, 409
- thyroid hormones 414, 415, 416
- thyroid receptor (TR) 28
- thyroid response elements (TREs) 415
- tissue-selective action 352
- tissue-selective agonist activity 9, 349
- tissue-selective AR modulator 12
- tissue-selective synthetic modulators 9
- tissue-specific PR ligands 210
- tissue-type plasminogen activator 163
- toll-like receptor (TLR) 334
- toremifene 90, 151
- combination therapy 90
- transactivation activity 442
- transactivation assays 204
- transactivation/transrepression hypothesis 320
- transcription factors 431, 433
- transcription regulators 251
- transcriptional regulator 283
- tricyclic tetrahydronaphthofuranone core ring system 212
- trifluoroethanol pharmacophore 315
- tyrosine aminotransferase (TAT) 314
- tyrosine hydroxylase (TH) 434
- u**
- ubiquitin-conjugating ligases 149
- ubiquitin-mediated degradation 170

- ubiquitin-ubiquitin linkage 150
 - University of California in San Francisco (UCSF) 318
 - University of Tennessee Health Science Center (UTHSC) 256
 - unsaturated fatty acids 370
 - upstream promoter transcription factor 367
 - US National Institutes of Health Consensus Development Conference 137
- v**
- vascular endothelial growth factor (VEGF) 230
 - vasoactive intestinal peptide (VIP) 434
 - ventricular hypertrophy 421
 - versatile gene regulation system 415
 - vitamin D metabolites 326
 - vitamin D receptor (VDR) 225, 326, 334, 421
 - agonists 333, 345
 - heterodimerizes 328
 - ligands 331, 334, 345
 - vitamin D-responsive elements (VDRE) 328
 - VDR/RXR heterodimer 337
- w**
- Wadsworth–Emmons reaction 351
 - water-mediated hydrogen bonds 156, 277
 - wedge-shaped hydrophobic ligand-binding cavity 130
 - wild-type mice 50, 54
 - Wyeth–Ligand collaboration 95
 - Wyeth’s in-house compound collection 78
- x**
- X-ray analysis 68, 75, 79, 81, 98, 99, 110
 - X-ray crystal structures 205
 - X-ray crystallography 38, 138, 148, 149, 166
 - unique aspect 166
 - Xenopus oocytes* 283
- y**
- yeast two-hybrid assay 76
- z**
- Zeitgeber’s Time (ZT) 432
 - zinc finger motifs 369
 - zymosan-induced paw edema model 319